Search Clinical Trials

The goal of this clinical study is to learn more about the safety and tolerability of obeldesivir (ODV) in children and adolescents with coronavirus disease 2019 (COVID-19).

主要目的是评估血浆药代动力学(PK)。, ODV在小儿COVID-19患者中的安全性和耐受性.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

The goal of this study is to understand how pregnant women and their newborn babies respond to SARS-CoV-2 infection in pregnancy, the virus responsible for COVID-19. The two main purposes of the study are: 1) to evaluate for the presence of the virus and development of antibodies in pregnant women diagnosed with COVID-19 and their newborn infants over time, 2)监测相同血液样本中疾病严重程度的标志物. The research study will last one year. We will collect blood samples from you to check for the presence of antibodies and markers of disease severity at the time of enrollment, at delivery, 6-weeks, 6-months and 12-months. 我们将在你的宝宝出生后24小时(在医院)采集血液样本, with routine labs), at 6 months, and 12 months. 我们还会在分娩时收集您的鼻咽拭子，以检测您的鼻子中是否存在病毒, and from your baby within 48 hours of life. 我们希望您和您的宝宝参加本次研究共4次访问, 每次评估持续约30分钟，直到出生后1年.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

COVID-19 can trigger a dysregulated immune response, 先前的研究表明，免疫调节可以改善住院患者的预后. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement.

需要治疗来改善COVID-19住院患者的预后, 包括直接作用抗病毒药物(DAA)，以减轻由正在进行的病毒复制驱动的病理. This trial will evaluate S-217622 (ensitrelvir), Shionogi开发的抗sars - cov2 3c样蛋白酶抑制剂(PI &; Co. Ltd.

The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. SOC将由当地制定的指南确定，并可能包括额外的DAA(例如.g., remdesivir) and immunomodulatory treatment strategies. 在随机化之前，将预先指定某些SOC治疗.

本临床试验的目的是了解其安全性, 药代动力学(药代动力学帮助我们了解服药后药物是如何变化和从体内排出的), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19).

The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.

This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, 在皇冠hga020电脑版环境中，可将其纳入COVID-19规划和后续治疗计划.

This protocol is a prospective, multi-center, multi-arm, randomized, 对照平台试验评估pasc介导的认知功能障碍的潜在干预措施. 假设是PASC与认知领域的功能障碍有关, such as executive function and attention, 是否可以通过选择性地加强这些领域的干预来改善.

This CDC sponsored surveillance project is designed to assess risk exposures and COVID-19 infections among working emergency department personnel. 该项目将要求参与者提供有关风险暴露的持续信息, 并将收集有关机构和皇冠hga020电脑版风险的额外信息. 这些风险评估将与疾病状况评估结合起来, as determined by serologic testing at two-week intervals. The goal of the project is to identify the most important and potentially correctable risk factors that emergency department personnel face while dealing in with the coronavirus pandemic.

This study seeks to determine if administration of the drug belumosudil (KD025) will be safe and improve transplant tolerance in subjects undergoing combined Human Leukocyte Antigen (HLA) single haplotype-matched related or 0-3 antigen (at A, B, C, HLA错配无亲缘关系活体供体肾和造血干细胞移植.

This study has not yet been registered on ClinicalTrials.Gov，这是目前显示详细资格标准的先决条件.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson综合癌症中心的法规遵从办公室.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.

目前的试点研究将招募有新经历的参与者, returning, 或在首次感染SARS-CoV-2后至少四周内出现与COVID-19疾病相关的持续症状. 所有参与者都将参加一个名为“正念意识练习”(MAPs)的虚拟课程，为期6周, hosted and led by expert facilitators from the Mindful Awareness Research Center (MARC) at University of California Los Angeles (UCLA). This intervention will consist of a mix of lecture, practice, group feedback, and discussion regarding mindfulness. Mindfulness is the mental state achieved by focusing one's awareness on the present while acknowledging and accepting any feelings, thoughts, or bodily sensations. 研究小组将收集心理健康症状的自我报告, physical health symptoms, 以及参与者参加MAPs前后的人口统计信息. 研究小组还将收集客观的健康措施，包括主动站立测试, a 6-minute walk, and a blood sample.

本研究将评估GWP42003-P的疗效, compared with placebo, 减轻自闭症谱系障碍(ASD)儿童症状严重程度的作用.

The purpose of this study is to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.